Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: Analysis of 138 consecutive patients

Virology Journal

Volumn 9, Issue , 2012, Pages

  Jin, Young Joo ^a   Kim, Kang Mo ^a   Yoo, Dong Jun ^a   Shim, Ju Hyun ^a   Lee, Han Chu ^a   Chung, Young Hwa ^a   Lee, Yung Sang ^a   Suh, Dong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Biochemical breakthrough; Chronic hepatitis B; Hepatitis flare; Lamivudine cessation; Virologic relapse

Indexed keywords

ALANINE AMINOTRANSFERASE; DNA; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; DISEASE COURSE; DNA VIRUS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; RELAPSE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; WITHHOLDING TREATMENT; YOUNG ADULT;

HEPATITIS B VIRUS;

EID: 84867551615     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-239     Document Type: Article

References (29)

1. Hepatitis B virus infection. Dienstag JL, N Engl J Med 2008 359 1486 1500 10.1056/NEJMra0801644 18832247
2. Lamivudine for patients with chronic hepatitis B and advanced liver disease. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, et al. N Engl J Med 2004 351 1521 1531 10.1056/NEJMoa033364 15470215 (Pubitemid 39315319)
3. Chronic hepatitis B: update 2009. Lok AS, McMahon BJ, Hepatology 2009 50 661 662 10.1002/hep.23190 19714720
4. Prevention of hepatocellular carcinoma in hepatitis B virus infection. Lim SG, Mohammed R, Yuen MF, Kao JH, J Gastroenterol Hepatol 2009 24 1352 1357 10.1111/j.1440-1746.2009.05985.x 19702903
5. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, Fung J, Yuen JC, Lai CL, Antivir Ther 2007 12 1295 1303 18240869
6. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, et al. Gastroenterology 2003 125 1714 1722 10.1053/j.gastro.2003.09.033 14724824 (Pubitemid 37500436)
7. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, Tzourmakliotis D, Manesis E, Hadziyannis SJ, Hepatology 2005 42 121 129 15962291 (Pubitemid 40911319)
8. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. European Association For The Study Of The L, J Hepatol 2012 57 167 185 22436845
9. The economics of treating chronic hepatitis B in Asia. Dan YY, Aung MO, Lim SG, Hepatol Int 2008 2 284 295 10.1007/s12072-008-9049-2 19669256
10. Economic evaluation of the societal costs of hepatitis B in South Korea. Yang BM, Paik SW, Hahn OS, Yi DH, Choi MS, Payne S, J Gastroenterol Hepatol 2001 16 301 308 10.1046/j.1440-1746.2001.02443.x 11339422 (Pubitemid 32374846)
11. Evaluation and management of hepatitis B in pregnancy: a survey of current practices. Ahn J, Salem SB, Cohen SM, Gastroenterol Hepatol (N Y) 2010 6 570 578
12. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Lee HC, Suh DJ, Ryu SH, Kim H, Shin JW, Lim YS, Chung YH, Lee YS, Gut 2003 52 1779 1783 10.1136/gut.52.12.1779 14633962 (Pubitemid 37510403)
13. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Lee HW, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, Park JY, Kim Do Y, Ahn SH, Paik YH, et al. Hepatology 2010 51 415 421 10.1002/hep.23323 19902424
14. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Clin Gastroenterol Hepatol 2008 6 1315 1341 10.1016/j.cgh.2008.08.021 18845489
15. Chronic Hepatitis B Guideline Work: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GKK, Locarnini S, Hepatol Int 2008 2 263 283 10.1007/s12072-008-9080-3 19669255
16. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW, Hepatology 2000 32 635 639 10.1053/jhep.2000.16333 10960461
17. Determinants for sustained HBeAg response to lamivudine therapy. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF, Hepatology 2003 38 1267 1273 10.1053/jhep.2003.50458 14578866 (Pubitemid 37314836)
18. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS, Hepatology 2009 50 1064 1071 10.1002/hep.23145 19637288
19. Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B. Shin JW, Park NH, Park JH, Park JH, Jeong ID, Bang SJ, Joo KR, Kim DH, J Viral Hepat 2005 12 393 397 10.1111/j.1365-2893.2005.00606.x 15985010 (Pubitemid 40961479)
20. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Dienstag JL, Schiff ER, Mitchell M, Casey DE Jr, Gitlin N, Lissoos T, Gelb LD, Condreay L, Crowther L, Rubin M, Brown N, Hepatology 1999 30 1082 1087 10.1002/hep.510300427 10498663 (Pubitemid 29458300)
21. Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment. Akuta N, Suzuki F, Kobayashi M, Matsuda M, Sato J, Suzuki Y, Sezaki H, Hosaka T, Someya T, Saitoh S, et al. Intervirology 2005 48 174 182 10.1159/000081746 15812192 (Pubitemid 41201508)
22. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS, Hepatology 2000 32 803 806 10.1053/jhep.2000.16665 11003626
23. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan. Huang YH, Wu JC, Chang TT, Sheen IJ, Lee PC, Huo TI, Su CW, Wang YJ, Chang FY, Lee SD, J Viral Hepat 2003 10 277 284 10.1046/j.1365-2893.2003.00428.x 12823594 (Pubitemid 36801914)
24. End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. Liu CJ, Huang WL, Chen PJ, Lai MY, Kao JH, Chen DS, World J Gastroenterol 2004 10 3574 3578 15534909
25. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF, Gut 2000 46 562 568 10.1136/gut.46.4.562 10716688 (Pubitemid 30305823)
26. Lamivudine as initial treatment for chronic hepatitis B in the United States. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA, N Engl J Med 1999 341 1256 1263 10.1056/NEJM199910213411702 10528035 (Pubitemid 29489740)
27. Distribution of hepatitis B virus genotypes in Korea. Cho JH, Yoon KH, Lee KE, Park DS, Lee YJ, Moon HB, Lee KR, Choi CS, Cho EY, Kim HC, Korean J Hepatol 2009 15 140 147 10.3350/kjhep.2009.15.2.140 19581766
28. Quantitative Serum HBV DNA levels During Different Stages of Chronic Hepatitis B Infection. Chi-Jen C, Munira H, Anna S, Lok F, Hepatology 2002 36 1 408 1415
29. Low level hepatitis B viremia detected by polymerase chain reaction accompanies the absence of HBe antigenemia and hepatitis in hepatitis B virus carriers. Niitsuma H, Ishii M, Miura M, Kobayashi K, Toyota T, Am J Gasrroenterol 1997 92 119 123 (Pubitemid 27027041)